Selected data models

You must log in to select data models for download or further analysis.

14 Search results.
Relevance Rating New first Old first

Eligibility Lymphoma NCT00275106

- 9/20/21 - 1 form, 1 itemgroup, 18 items, 1 language
Itemgroup: Criteria
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00275106

Eligibility Lymphoma NCT00290433

- 9/20/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290433

Eligibility Cutaneous T-Cell Lymphoma NCT00744991

- 9/17/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00744991

Eligibility T-cell Non-Hodgkin's Lymphoma NCT00655668

- 11/6/18 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00655668

Eligibility T-cell Lymphoma NCT00959686

- 11/6/18 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00959686

Eligibility T-Cell Lymphoma NCT00542919

- 11/6/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study for Patients With Non-Hodgkin's Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT00542919

Eligibility T Cell Non-Hodgkin Lymphoma NCT00684411

- 11/5/18 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00684411

Eligibility Lymphoma, T-Cell NCT00418535

- 4/28/17 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00418535

Eligibility T-Cell Lymphoma NCT00161590

- 12/27/16 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00161590

Eligibility T-cell Lymphoma NCT00001582

- 2/22/16 - 1 form, 2 itemgroups, 24 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00001582

Eligibility Peripheral T Cell Lymphoma NCT00970385

- 2/18/16 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00970385

Eligibility T-cell Lymphoma NCT02424045

- 1/3/16 - 1 form, 2 itemgroups, 28 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02424045

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial